AJR AJR-based Continuing Ed for Technologists
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Kelloff, G. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelloff, G. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.09.2579
AJR 2009; 192:1455-1470
© American Roentgen Ray Society


Review

Challenges in Clinical Prostate Cancer: Role of Imaging

Gary J. Kelloff1, Peter Choyke2, Donald S. Coffey3 for The Prostate Cancer Imaging Working Group

1 Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Institutes of Health, National Cancer Institute, 6130 Executive Blvd., EPN Rm. 6058, Bethesda, MD 20852.
2 Molecular Imaging Program, National Institutes of Health, National Cancer Institute, Bethesda, MD.
3 Department of Urology, Johns Hopkins University, Baltimore, MD.

OBJECTIVE. This article reviews a recent 2-day workshop on prostate cancer and imaging technology that was conducted by the Cancer Imaging Program of the National Cancer Institute. The workshop dealt with research trends and avenues for improving imaging and applications across the clinical spectrum of the disease.

CONCLUSION. After a summary of prostate cancer incidence and mortality, four main clinical challenges in prostate cancer treatment and management—diagnostic accuracy; risk stratification, initial staging, active surveillance, and focal therapy; prostate-specific antigen relapse after radiation therapy or radical prostatectomy; and assessing response to therapy in advanced disease—were discussed by the 55-member panel. The overarching issue in prostate cancer is distinguishing lethal from nonlethal disease. New technologies and fresh uses for established procedures make imaging effective in both assessing and treating prostate cancer.

Keywords: diffusion-weighted MRI • dynamic contrast-enhanced MRI • FDG PET imaging • functional imaging • high-intensity focused ultrasound imaging • MRI • prostate cancer imaging • SPECT


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JNMHome page
A. Zaheer, S. Y. Cho, and M. G. Pomper
New Agents and Techniques for Imaging Prostate Cancer
J. Nucl. Med., September 1, 2009; 50(9): 1387 - 1390.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Roentgen Ray Society.